Pradimicin A (Fig. 1) has been found as a new antifungal antibiotic in the culture filtrate of Actinomadura hibisca sp. nov. Strain PI57-2 (ATCCS^Sl).1"^In this communication, we describe that the antibiotic and its imino derivative efficiently inhibit the human T-lymphotropic virus type IIIB (HTLV-IIIB)-induced cyctopathic effect of MT-4cells and the cell fusion by cell to cell infection and syncytia formation in the cocultures of MOLT-4 and MOLT-4/human immunodeficiency virus (HIV)HTLV_IIIB cells. The number of viable MT-4 cells infected with HIV at a multiplicity of infection of 0.002 decreased during the cultivation and almost all cells were dead by 6 days after infection as determined by a trypan blue dye exclusion method.4) When pradimicin A (1) and imino derivative (2) were added to the culture, the cell damage induced by HIV was significantly suppressed at the concentrations more than 3.5 iMg/ml of compounds (Fig. 2) . With regard to cytotoxicity of 1 and 2, almost no growth inhibition of MT-4cells was observed at the concentrations up to 30^g/ml.
Higher concentrations of 1 and 2 showed only weak growth inhibition against MT-4 cells. Cell size distribution of MOLT-4(A), MOLT-4/HIVHTlv-iiib (B) and coculture of both cell lines (C) was analyzed by a cell multisizer. A portion of particles with more than 20 jum in diameter was dotted. Effect of dextran sulfate (D), pradimicin A (E) and imino derivative (F) was examined at the concentrations of 50 A«g/ml, 25^g/ml and 25 jug/ml, respectively.
Experssion of HIV antigen as revealed by immunofluorescencewas significantly suppressed when HIV-infected MT-4cells were cultured in the presence of 1 and 2, and positive cells were only less than 1% at the concentrations more than 3.5 A*g/ml of both 1 and 2 (data not shown).
Wenext inquired the effect of these compounds on the multinucleated giant cell formation. MOLT-4and MOLT-4/HIVHTlv-iiib cells were mixed in a 1 : 1 ratio in proportion of cell number and incubated for 20 hours at 37°C. Then the size of particles was measured and the diameter was plotted on the horizontal axis by a cell multisizer.5) Fig. 3 ll.8%. When 1 and 2 were added to cocultures, giant cell formation was apparently suppressed at the concentrations more than 12.5^g/ml. The viable cells in each culture were also counted and the fusion index (FI) value was calculated as described previously.6) Control culture without compoundshowed the FI value of 1.71. The FI value of the culture containing 50 jug/ml of dextran sulfate, which completely inhibitied the giant cell formation, was 0.12 and the culture containing 50 /^g/ml and 25 ywg/ml of 1 and 2 showed the FI value of less than 0.2 (data not shown). 1 and 2 did not inhibit avian myeloblastosis virus (AMV) reverse transcriptase (1 u) even at the concentration of 100^g/ml (data not shown).
From the results 1 and 2 showed the anti-HIV activity at the concentrations more than 3.5^g/ ml in the cell-free infection with MT-4cells.
More importantly, they showed inhibitory activity to the HIV-induced giant cell formation at the concentrations more than 12.5 yMg/mlin coculture system. In the presence of 1 or 2 size distribution pattern of cells in the cocultures was similar to that in the culture with dextran sulfate used as a positive control (Figs. 3D~3F) . On the other hand, these compounds did not inhibit the AMV reverse transcriptase. These results strongly suggest that 1 and 2 exert their anti-HIV activity on the step of viral adsorption.
1 and 2 are shown to have antiviral activity against influenza virus.2) Very recently, Takeuchi et al. also reported that benanomicin,7) which has closely related structure to 1, was active against fungi and some Gram-positive bacteria. At present we do not knowthe reason why 1 or benanomicin is active against such various species of microorganisms. 1 and 2 scarcely inhibited the growth of MT-4 cells and chemotherapeutic indices showed relatively large. Therefore, it is worthy to study these compounds more extensively in terms of chemotherapeutic and/or prophylactic point of view against AIDS and ARC. NOV. 1988 
